| SPONSORED | "I've Never Recommended Something Like This Before" Has the world's greatest stock picker gone mad? He picked Amazon, Netflix, Apple... And now this? Alexander Green makes a BOLD prediction to a huge crowd in his latest TEK Talk... And it might just help set you up for retirement. Click here to see more. | The Three Hottest Technologies to Invest in Today |  | By Andy Snyder, Founder |
| | | In late November, we told a small group of our paid readers about a tiny stock that recently IPO'd.
Back then, it traded for about $8 per share.
As we rang in the new year, shares were worth more than $32.
The company is a biotech that's pioneering not just a new type of medicine... but a new form of medicine. The work it's doing challenges science that was believed to be fact only five years ago.
Its latest project just got through a key stage of FDA trials, and investors are making good money.
Technophile or Technophobe?
Over the years, we've (wrongly) become known as a bit of a technophobe.
The idea is far from reality. We would never shun technology that has the ability to better our lives.
But we do have our principles. They're simple.
We'll never give a nod to tech that threatens our physical, mental or social health.
You'll never hear us being interviewed about the latest innovations in TV displays or social media platforms.
But just before Christmas, for instance, we agreed to join a popular tech podcast to share our views on some strong, healthy technology... the booming satellite industry.
And if you're a Manward Letter subscriber, you know our popular Modern Asset Portfolio dedicates some 40% of its allocation to the roaring potential of cryptos and disruptive stocks like we've seen from the tech sector.
No doubt, technology is going to lead to some of the biggest gains of the next 12 months.
We have our thumb on three specific spaces... with our fingers outstretched, always searching for more. | | | | SPONSORED | The Next Dividend Champions? Today, Oxford Club Chief Income Strategist Marc Lichtenfeld is revealing the 12 dividend stocks he believes could become the next "Dividend Champions"... And if you're serious about building income for retirement, you won't want to miss out. Details here... |
| | | What We're Watching
When it comes to high-tech wizardry, the space industry is leading the charge. It's a libertarian investor's dream... especially what's happening in the satellite sector.
We've written about it before.
The private sector - including companies like one of last year's hottest special purpose acquisition company (SPAC) trades, Virgin Galactic (SPCE) - has pushed the government aside and made vast leaps in a short time.
We're now using private spacecraft to regularly send cargo (including humans) into space.
We expect satellite communication to soon replace its land-based cellular competition. Massive improvements have been made in recent months. And thanks to some of the latest breakthroughs, you won't need a new phone to hook up to a satellite.
But there's a smaller piece of the space race that doesn't get the attention it deserves. It has to do with medicine.
Thanks to cheaper rockets and a private sector that's good at using them, individual scientists are now sending small experiments into space at a quickly growing clip. For a relatively low price, researchers can send their work into the heavens, where the antigravity effects hasten the results and accomplish tasks that can't be done here on the ground.
It's adding strong momentum to the breakthroughs in the realm of personalized medicine... the second tech arena we're excited about.
Just for You
The company we recently told our subscribers about has helped discover that cancer cells speak a different language than healthy cells. And because of that, it's working on an entirely new class of medicine.
We all know that current cancer treatments are nasty. They leave patients sick, weak and praying for relief. This tiny company just passed its first test in ending that problem.
Its treatment goes beyond the DNA level and puts the medicine directly on the problem... with a highly precise dose.
As the technology evolves, it will become more and more personalized. Docs will decipher a patient's DNA, use an algorithm to develop the best approach and administer treatment in the exact right dose and location.
No more "shock and awe" treatments that open the body to a host of other killers.
The messenger RNA (mRNA) COVID-19 vaccine developed by Moderna (MRNA) represents the first step in this evolution.
But Dr. Yusuf Erkul says Moderna is an mRNA 1.0 company.
Sure, it's a pioneer in the industry. But he says his company - privately owned Kernal Biologics - is working on mRNA 2.0.
It's working on much more specific treatments - treatments that affect only cancer cells and not the healthy cells around them.
In October, by the way, Erkul sent his work to space, where the doc believes the lack of gravity will speed up his tests and bring a much higher likelihood of success.
It's amazing stuff.
Central Bank Alternative
Finally, like it or not, one of the hottest technologies these days is within the realm of digital money.
Frequent readers would be disappointed - or think I'm sick - if I didn't mention the trend.
What's happening here is fascinating... once again bringing a smile to the faces of Liberty lovers across the globe.
Blockchain and cryptocurrencies have created not only a decentralized check on out-of-control central bank money printing but also new ways for the efficient market to do its job.
You've probably heard that all sorts of institutional investors are getting into the crypto game. Just this week, in fact, the fine folks at JPMorgan (JPM) announced a new $146,000-plus price target for Bitcoin.
But what's not getting much attention are the many ways hedge funds and Wall Street's big boys are using cryptos.
Oh sure, PayPal (PYPL) and Square (SQ) are driving up prices as they buy all the coins they can to support their new dollar-threatening initiatives... but it's the sophisticated traders who are adding the grease that will allow this machine to spin like never before.
Still in its infancy, the crypto market remains highly inefficient. Huge moves from one day to the next prove it.
There's big money to be made in getting rid of those inefficiencies. Just as high-frequency traders have helped narrow the gap between bid and ask spreads, big-league investors are doing the same in the world of digital investing.
Bitcoin futures, for instance, are the tool of choice for these players. Contracts are seeing massive volume - with more than $1.5 billion worth of open interest at the moment.
That's good news for a company that few associate with high technology - CME Group (CME). It's a company that's been in our Modern Asset Portfolio since June.
It's the central hub for many digital currency derivatives.
It proves that science takes all shapes and sizes.
We've seen big breakthroughs in recent years. Some make our lives worse. They must be shunned.
But much of the technology leads to efficiency, better health and, our darling, Liberty.
Bottom line... Invest in all three of the technologies above.
They're making the world a better place.
Be well,
Andy
Which of these three technologies has you the most excited? Share your thoughts at mailbag@manwardpress.com. | | |
|
No comments:
Post a Comment
Keep a civil tongue.